Selkirk Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Selkirk Pharma is a private, purpose-built sterile fill/finish CMO established to address industry bottlenecks in injectable drug manufacturing. The company operates a state-of-the-art, Pharma 4.0-enabled facility in Spokane, Washington, offering vial filling from 0.5mL to 50mL with high throughput and yield. Led by industry veterans, Selkirk targets biopharma companies needing reliable, US-based capacity for clinical and commercial drug product, positioning itself as a strategic partner for onshoring supply chains and mitigating contamination and shortage risks.

Drug DeliveryBiologicsSmall Molecules

Technology Platform

Advanced sterile fill/finish manufacturing facility featuring fully automated isolator filling lines, Pharma 4.0 data infrastructure, in-house analytical testing, and a proprietary fast-track service program (ClinFAST™) for clinical trial materials.

Opportunities

Strong demand driven by chronic industry-wide capacity constraints for sterile fill/finish and a strategic push to onshore pharmaceutical manufacturing to the US for supply chain security.

The growing pipeline of injectable biologics and small molecules, particularly from small and mid-sized biotechs, provides a large and sustained client base.

Risk Factors

Operational and reputational risk is concentrated in a single facility, where any contamination event or regulatory compliance issue could be catastrophic.

The company faces intense competition from large, established CMOs and must successfully fill its capacity to cover the high fixed costs of its new facility.

Competitive Landscape

Selkirk competes in the crowded contract fill/finish market against global giants like Catalent, Lonza, and Baxter Biopharma Solutions, as well as numerous specialized and regional CMOs. Its differentiation is based on being a new, purpose-built facility with available US capacity, a focus on client service via expert teams, and the ClinFAST™ program for speed in clinical trials.

More companies in Biologics / Biosimilars →More companies in United States →